Arcturus Therapeutics Holdings Inc
ARCTHealthcare|Biotechnology|USA
$6.97
-0.19 (-2.65%)
Tangible Book
$6.73
Clinical Trials (16)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06747858 Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis | Cystic Fibrosis, CFTR Gene Mutation | P2 | Recruiting | 33 | Open-label | ARCT-032 |
| NCT06488313 A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD | OTC Deficiency, Ornithine Transcarbamylase Deficiency | P2 | Recruiting | 9 | Open-label | ARCT-810 |
| NCT06279871 Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults | COVID-19 | P3 | Completed | 1,514 | RCT, Double-blind | ARCT-2303, Influenza vaccine, Influenza vaccine, adjuvanted |
| NCT05012943 The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) | COVID-19 Vaccines | P2P3 | Completed | 19,474 | RCT, Double-blind | ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine, Astra Zeneca COVID-19 vaccine |
| NCT05526066 Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 | Ornithine Transcarbamylase Deficiency, OTC Deficiency | P2 | Terminated | 8 | RCT, Double-blind | ARCT-810 |
| NCT04728347 Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021 | SARS-CoV-2 | P2 | Terminated | 65 | Open-label | ARCT-021 |
| NCT04668339 A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults | Covid19, SARS-CoV Infection | P2 | Terminated | 581 | RCT, Double-blind | ARCT-021 single dose priming, ARCT-021 two lower dose priming, ARCT-021 two higher dose priming, Placebo (two doses), priming, Randomized booster, Placebo booster |
| NCT05037097 A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults | COVID-19, SARS-CoV-2 Infection | P1P2 | Completed | 72 | RCT, Double-blind | ARCT-165, ARCT-154, ARCT-021 |
| NCT04480957 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects | SARS-CoV-2 | P1P2 | Completed | 106 | RCT, Double-blind | ARCT-021 Dose 1, ARCT-021 Dose 2, ARCT-021 Dose 3, ARCT-021 Dose 4, ARCT-021 Dose Regimen 1, ARCT-021 Dose Regimen 2 |
| NCT07390968 Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients | Hematopoietic and Lymphatic System Neoplasm | P2 | Not Yet Recruiting | 56 | RCT, Double-blind | SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran |
| NCT05712538 Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis. | Cystic Fibrosis | P1 | Completed | 39 | RCT, Double-blind | ARCT-032 |
| NCT06125691 Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults | Influenza, Human | P1 | Completed | 139 | RCT, Double-blind | ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine for older adults |
| NCT04442347 Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency | Ornithine Transcarbamylase Deficiency | P1 | Completed | 16 | RCT, Double-blind | ARCT-810 |
| NCT04416126 Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects | Ornithine Transcarbamylase Deficiency | P1 | Completed | 30 | RCT, Double-blind | ARCT-810 |
| NCT06602531 Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults | Influenza, Human | P1 | Completed | 212 | RCT, Double-blind | ARCT-2304, Control vaccine (licensed seasonal influenza vaccine) younger adults, Control vaccine (licensed seasonal influenza vaccine) older adults |
| NCT07201818 LET for Fibromyalgia | Fibromyalgia | N/A | Not Yet Recruiting | 40 | RCT, Single-blind | — |